We further explored the clinical utility of a logistic regression-based predictive model to identify potential blood-based immune biomarkers to select the subset of patients with EGFR-mutated, EGFR-TKI-resistant NSCLC who will most likely benefit from the combination of Chemo+ICIs. Here, EGFR is linked to non-small cell lung carcinoma.